OTC Continuous Glucose Monitors: Should Non-Diabetic Seniors Use One?

For the first time, any adult in the United States can walk into a pharmacy — or order online — and get a continuous glucose monitor (CGM) without a prescription. Dexcom Stelo and Abbott Lingo both received FDA clearance for over-the-counter use in 2024, and by April 2026 they're genuinely widely available. No insulin? No diabetes diagnosis? Doesn't matter. You can buy one.

The question for readers 60+ is whether you should. This is an honest look at what a CGM actually tells you, who benefits most, who's wasting their money, and what the real monthly cost is.

This article is informational and not medical advice. Talk to your doctor before making health decisions.

What is a CGM?

A continuous glucose monitor is a small sensor — about the size of a two-pound coin or a quarter — that sticks to the back of your upper arm with an adhesive patch. A tiny filament sits just under the skin and measures glucose in the fluid around your cells every minute or two. The data is sent by Bluetooth to your phone, which shows your glucose trend throughout the day and night.

Traditional CGMs (Dexcom G7, Abbott FreeStyle Libre 3) were designed for people with diabetes and required a prescription. The new OTC versions — Stelo and Lingo — are designed for people without diabetes who want to understand their metabolic health.

Stelo vs Lingo — the basics

Both are available at CVS, Walgreens, Walmart, Amazon, and directly from each manufacturer's website.

Prices verified from stelo.com and hellolingo.com as of April 2026.

Which seniors will actually benefit

In my experience reviewing these for readers 60+, three groups get real value:

1. Pre-diabetic adults who want to head off full diabetes

If you've been told "your fasting glucose is borderline" or "your A1c is 5.9" (A1c is a blood test that averages your glucose over the past 3 months — above 6.5 is diabetes; 5.7–6.4 is prediabetes), a two-month CGM trial is a genuinely useful investment. You'll learn:

• Which foods in your usual diet spike your glucose the most. For some seniors it's oatmeal, for others it's a specific brand of bread, for others it's orange juice.
• Whether a 15-minute walk after dinner flattens your glucose response (it usually does).
• Whether you're waking up with higher overnight glucose than you realised (sometimes a sign of dawn phenomenon or poor sleep).

Two months of data is usually enough to see your patterns. After that, most people don't need to keep wearing one.

2. Adults on medications that affect glucose

Certain medications — corticosteroids like prednisone, some blood pressure medications (thiazide diuretics), some anti-psychotics — can raise blood glucose. If you've been started on one and you're worried, a 4-week CGM run lets you and your doctor see if there's a real effect.

3. Adults with a strong family history of type 2 diabetes

If both parents or multiple siblings have type 2 diabetes and you're 60+, you're at higher risk. A CGM isn't a replacement for routine A1c testing — but it can catch a problem earlier.

Who shouldn't bother

Being equally honest:

• If you've already been diagnosed with type 1 or type 2 diabetes — don't use Stelo or Lingo. Use a prescription CGM (Dexcom G7 or Abbott Libre 3) that's designed for treatment decisions and is covered by Medicare and most insurance.
• If you're on insulin — the OTC CGMs explicitly state they are not for anyone using insulin. The data is not precise enough for insulin dosing decisions.
• If you're curious for a week — don't bother. One week isn't enough data to see meaningful patterns. You need at least 2–3 weeks and ideally 4.
• If you have an eating disorder history. CGMs can be intensely triggering for hyper-focus on food, and doctors generally advise against them for this group.
• If you can't afford to lose US$89–99/month and keep going. One month probably won't teach you enough. Two will.

What you'll actually see on the app

A typical trend line for an over-60 non-diabetic on a moderate-carb day might show:

• Morning (fasting): 85–100 mg/dL.
• After breakfast: rises to 130–150 mg/dL, back to baseline in 90 minutes.
• Late morning dip: back to around 90.
• After lunch: rises to 140–160, back to baseline in 2 hours.
• Afternoon: around 95–100 with small wiggles.
• After dinner: rises to 130–170 depending on what was eaten, returns by bedtime.
• Overnight: 85–100 with slow oscillations.

Anything above 180 mg/dL sustained, or above 200 after a normal meal, suggests impaired glucose tolerance and is worth talking to your doctor about.

Plain English on glucose numbers

• Normal fasting glucose: under 100 mg/dL (under 5.6 mmol/L in UK/AU units).
• Pre-diabetes fasting: 100–125 mg/dL (5.6–6.9 mmol/L).
• Diabetes fasting: 126 mg/dL or higher (7.0 mmol/L or higher), confirmed twice.
• Normal 2-hours-after-meal: under 140 mg/dL (7.8 mmol/L).
• Time-in-range target for non-diabetics: 90% of the day between 70 and 140 mg/dL.

CGM readings can differ from a fingerstick blood test by 10–15%. For any important decision, confirm with a lab test through your doctor.

How to actually use a CGM as a senior

• Place the sensor on the back of your upper arm, in a spot where it won't be knocked against walls or doorframes. Most people lose their first sensor within a few days by banging it on something.
• Wear a long sleeve for the first hour to stop the adhesive pulling off during the warm-up.
• Pair with your phone before applying — the app walkthroughs are good. But if you're not comfortable with the app, a teenage grandchild can do this in 5 minutes.
• Log what you eat and when you exercise in the app. This is what makes the data useful. If you just see numbers without context, you'll learn almost nothing.
• Don't panic at spikes. Everyone spikes after carbs. What matters is how fast you come back down.
• Compare notes with your doctor at your next visit. Export the data as a PDF from the app and bring it along.

Medicare and insurance in 2026

OTC CGMs (Stelo, Lingo) are generally not covered by Medicare or most insurance — they're consumer products. Prescription CGMs (Dexcom G7, FreeStyle Libre 3) are covered by Medicare Part B for diagnosed diabetics on insulin and for some non-insulin diabetics with documented hypoglycaemia. If you think you might qualify, talk to your doctor about a prescription-grade CGM — it'll be much cheaper than the OTC version.

For more on what Medicare covers in wearable health tech, see Medicare wearable coverage in 2026.

UK and Australia note

As of April 2026, OTC CGMs (Stelo, Lingo) are US-only. The UK NHS and Australian TGA have not yet approved OTC versions. In both countries, CGMs are available on prescription via your GP or specialist for people with diabetes. Abbott Lingo is available in the UK and parts of Europe directly to consumers through Abbott's own site for metabolic health — pricing there is approximately £89/month.

Red flags — call your doctor if

• You see sustained readings above 250 mg/dL without an obvious cause.
• You see readings below 70 mg/dL with symptoms of dizziness, sweating, or confusion — and especially if you're not on any diabetes medication.
• Any symptom of diabetic ketoacidosis — severe thirst, frequent urination, abdominal pain, fruity-smelling breath. Call your doctor or go to urgent care.

Related reading

• Apple Watch for seniors guide
• Smartwatch blood pressure accuracy 2026
• Medicare wearable coverage 2026
• Medicare telehealth 2026 walkthrough
• Emergency SOS setup for iPhone and Android

Sources

• US FDA, Dexcom Stelo Over-the-Counter Clearance, March 2024.
• US FDA, Abbott Lingo Over-the-Counter Clearance, September 2024.
• Dexcom, Stelo product information and pricing, stelo.com, accessed April 2026.
• Abbott, Lingo product information, hellolingo.com, accessed April 2026.
• American Diabetes Association, Standards of Care in Diabetes — 2026.
• NICE (UK), guidance on CGM eligibility, 2026 update.

This article is informational and not medical advice. Talk to your doctor before making health decisions.

✅ Reviewed by Eleanor Shaw — techfor60s editorial desk, last verified 2026-04-18.